- Human pathology

Home > A. Molecular pathology > Targeted therapy > Therapeutical antibodies > trastuzumab


Wednesday 6 June 2007

Her­ceptin ®

Trastuzumab is an anti-ErbB-2 (human epidermal growth factor receptor 2) monoclonal antibody.

Trastuzumab is widely used for advanced breast cancer patients with ERBB2-amplified tumors. Nevertheless, over half of these patients do not have an objective response.

Her­ceptin ® (trastuzumab) treat­ment is iden­ti­fied by the HER-2/neu recep­tor and is used in Breast can­cer: about 30% of can­cers have an over-expression of HER-2 pro­tein, which respond to Herceptin.

Trastuzumab improves survival rate in women with metastatic breast cancer.


Symptomatic heart failure, a serious adverse effect of trastuzumab, occurs in 1% to 4% of patients treated with the antibody, whereas left ventricular ejection fraction declines substantially in 10% of patients.

The prevalence of cardiotoxic effects of trastuzumab appears to increase with exposure to anthracyclines.

Patients who develop cardiotoxicity while receiving trastuzumab therapy generally improve once use of the agent is discontinued.

See also

- ERBB2 (HER2)


- Hudis CA. Trastuzumab—mechanism of action and use in clinical practice. N Engl J Med. 2007 Jul 5;357(1):39-51. PMID: 17611206


- Trastuzumab has preferential activity against breast cancers driven by HER2 homodimers. Ghosh R, Narasanna A, Wang SE, Liu S, Chakrabarty A, Balko JM, González-Angulo AM, Mills GB, Penuel E, Winslow J, Sperinde J, Dua R, Pidaparthi S, Mukherjee A, Leitzel K, Kostler WJ, Lipton A, Bates M, Arteaga CL. Cancer Res. 2011 Mar 1;71(5):1871-82. PMID: 21324925

- Combined cetuximab and trastuzumab are superior to gemcitabine in the treatment of human pancreatic carcinoma xenografts. Larbouret C, Robert B, Bascoul-Mollevi C, Penault-Llorca F, Ho-Pun-Cheung A, Morisseau S, Navarro-Teulon I, Mach JP, Pèlegrin A, Azria D. Ann Oncol. 2010 Jan;21(1):98-103. PMID: 19889608

- Trastuzumab for patients with axillary-node-positive breast cancer: results of the FNCLCC-PACS 04 trial. Spielmann M, Roché H, Delozier T, Canon JL, Romieu G, Bourgeois H, Extra JM, Serin D, Kerbrat P, Machiels JP, Lortholary A, Orfeuvre H, Campone M, Hardy-Bessard AC, Coudert B, Maerevoet M, Piot G, Kramar A, Martin AL, Penault-Llorca F. J Clin Oncol. 2009 Dec 20;27(36):6129-34. Epub 2009 Nov 16. PMID: 19917839

- Morrison LE, Jewell SS, Usha L, Blondin BA, Rao RD, Tabesh B, Kemper M, Batus M, Coon JS. Effects of ERBB2 amplicon size and genomic alterations of chromosomes 1, 3, and 10 on patient response to trastuzumab in metastatic breast cancer. Genes Chromosomes Cancer. 2007 Apr;46(4):397-405. PMID: 17243161